The occurrence of brain metastases in oncology has become an increasing frequency event. Their management is complex and aims to control the symptoms and avoid neurological degradation. Radiotherapy retains a prominent place in any therapeutic approach. However, their prognosis remains bleak. We report our experience in the management of these metastases. Retrospective study of 129 patients with cerebral metastases treated between January 2011 and December 2016 at the Oncology Department of the Mohammed VI University Hospital Center in Marrakech, Morocco. The mean age was 47.34 years (range 19 and 78 years). The sex ratio was 1.04. Clinical symptomatology was dominated by intracranial hypertension (95.65%), signs of focus (30%) and convulsive seizures (23.91%). Metastasis was indicative of the disease in 13% of cases. The primary focus was bronchial (37.3%), mammary (35.8%), digestive (10.2%), gynecological (6.6%), dermatological (4.3), urological (2.9%) and undetermined in 2.9% cases. The predominant histological types were infiltrating ductal carcinoma and bronchial adenocarcinoma. The lesions were multiple in 76.08% of the cases. Excision surgery was performed in 8.69% of cases. All patients were treated with brain radiotherapy according to two protocols; 30Gy in 10 sessions (78.26% of cases) and 20Gy in 5 sessions (21.73% of the cases). With an average follow-up of 7.3 months (between 1 month and 15 months), symptom improvement was observed in 63.04% of cases and neurocognitive disorders in 8.16% of cases. Radiotherapy retains a pivotal role in the treatment of brain metastases, although the optimal associations of systemic and local treatments remain to be defined